Advocating for Patients: Letter to the FDA on RP1 Treatment Access

Published:  
09/05/2025
Categories:  
Blog - Melanoma360
Image

Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed.

The full letter is embedded below for your reference. Click on the image to enlarge it, or download the PDF using the link beneath the letter.

Download the PDF here

Recent Posts

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Jun. 05, 2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

Filter by Tag